Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses results from the phase II NSGO-AVANOVA2/ENGOT-OV24 trial comparing niraparib (Zejula) with niraparib plus bevacizumab (Avastin) in patients with recurrent platinum-sensitive ovarian cancer.
Website: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
LinkedIn: [ Ссылка ]
